has been cited by the following article(s):
[1]
|
Cost-effectiveness and budget impact analysis of infliximab and its biosimilar in patients with refractory moderate-to-severe Crohn’s disease using real world evidence in Thailand
Journal of Medical Economics,
2020
DOI:10.1080/13696998.2020.1803889
|
|
|
[2]
|
Biosimilars for the Management of Inflammatory Bowel Diseases: Economic Considerations
Current Medicinal Chemistry,
2019
DOI:10.2174/0929867324666170406112304
|
|
|
[3]
|
Clinical effectiveness and cost-effectiveness of use of therapeutic monitoring of tumour necrosis factor alpha (TNF-α) inhibitors [LISA-TRACKER® enzyme-linked immunosorbent assay (ELISA) kits, TNF-α-Blocker ELISA kits and Promonitor® ELISA kits] versus standard care in patients with Crohn’s disease: systematic reviews and economic modelling
Health Technology Assessment,
2016
DOI:10.3310/hta20830
|
|
|